SYNE1 and prostate carcinoma: The use of Predict Prostate was associated with an increased likelihood of attending ROPD for men with CPG2 prostate cancer (OR = 2.155, 95% CI = 1.158–4.013, p = 0.015) but a reduced likelihood of proceeding with RARP for men with CPG2 (OR = 0.397, 95% CI = 0.209–0.753, p = 0.005) and CPG3 (OR = 0.305, 95% CI = 0.108–0.861, p = 0.025) prostate cancer.